
FDG-PET/CT Melanoma - Staging

Newly diagnosed melanoma:

- Non-visualization of primary tumor (after excision)
- 2. The primary tumor is located in the neck
- The patient has disseminated disease






FDG-PET/CT Melanoma - Staging

Newly diagnosed melanoma:

- Non-visualization of primary tumor (after excision)
- 2. The primary tumor is located in the neck
- 3. The patient has disseminated disease



Primary tumor - frontal scalp Nodal metastases - right axilla & left neck



Melanoma Performance of FDG Imaging


- Overall performance (Schwimmer, meta-analysis QJNM): sensitivity 92%, specificity 90%
- Stage 1-2 (>80% localized disease): limited use
- Stage 3 (<15% regional disease):

 Sensitivity 87%,PPV 91% (Tyler, Cancer 2000)

 Upstage to stage 4: 17% (Bastiaannet, Br J Surg 2006)
- Stage 4 (<5% metastatic disease): Sensitivity 94%, Specificity 83%



FDG-PET/CT, Melanoma of Upper Back S/a resection, Follow-up, Abdominal Pain




- 1. Negative FDG PET/CT
- 2. Multiple FDG+ sites: metastatic melanoma
- 3. Multiple FDG+ sites: 2nd primary colon ca with metastases
- 4. Multiple FDG+ sites: physiologic



FDG-PET/CT, Melanoma of Upper Back S/a resection, Follow-up, Abdominal Pain

- Negative FDG PET/CT
- 2. Multiple FDG+ sites: mets of melanoma
- 3. Multiple FDG+ sites: 2nd colon ca with mets
- 4. Multiple FDG+ sites: physiologic



Metastases in small bowel & mesenteric LN

Melanoma – Localization & Treatment


- Primary: Skin, Women extremities / Men trunk
- Metastases:
 - lymph nodes, skin, soft tissue, lung liver
 - unusual spread: GIT, myocardium, leptomeninges

Importance of correct staging - Treatment options

- Surgical excision treatment of choice for:
 - local disease
 - single regional LN
 - isolated distant metastases
- Limited success rate: limb perfusion chemotherapy, tumor vaccines, radiotherapy




Melanoma – Lt. Adrenal Metastasis Treatment Planning (Surgery?)




- 1. The patient has a single metastasis proceed with surgery
- 2. The patient has additional metastases surgery should be cancelled
- 3. The additional FDG+ focus in the right upper abdomen is according to the physiologic biodistribution of the tracer and of no clinical significance

Melanoma - Adrenal Mass Treatment Planning (Surgery?)




- 1. The patient has a single metastasis proceed with surgery
- 2. The patient has additional metastases surgery should be cancelled
- 3. The additional FDG+ focus in the right upper abdomen is within the physiologic biodistribution of the tracer and of no clinical significance






Melanoma - Adrenal Mass Treatment Planning (Surgery?)



- 1. Single metastasis proceed with surgery
- 2. The patient has additional metastases surgery should be cancelled
- 3. Additional FDG+ focus in the right upper abdomen, within the physiologic FDG biodistribution, of no clinical significance

Additional metastasis in retroperitoneal LN, retrospectively detected on CT



FDG-PET/CT in Melanoma Changes in Management

- Sparing unnecessary surgical procedures
 (4-24% clinically limited disease are non-resectable following FDG-PET/CT)
- Referral to previous unplanned surgery
- Referral/Addition of immuno/chemotherapy
- Addition of radiotherapy

250 pts: treatment change - 48%


Reinhardt, JCO, 2006



Metastatic Melanoma (repeat study after 4 mo) Monitoring Response to Immuno-/Chemo

The patient shows:


- 1. Complete response
- 2. Partial response
- 3. Stable disease
- 4. Tumor Progression



Metastatic Melanoma, Tumor Progression

The patient shows:

- 1. Complete response
- 2. Partial response
- 3. Stable disease
- 4. Tumor Progression



New Inguinal LN Metastasis

Melanoma Indications for FDG Imaging

- Detection of metastases (regional & distant)
- Staging of intermediate >2mm & high-risk > 4mm tumors
- Restaging of high-risk tumors
 - Low risk melanoma (thin <1mm):
 favorable prognosis; 15% chance for mets
 - High risk melanoma (thick >4mm):
 50-70% of all melanoma, 5year survival <50%, 10% distant mets,
- Extent of disease in clinically resectable disease
- Monitoring response to chemo- and radiotherapy
- Further evaluation of equivocal findings on CT
- Follow up in high-risk patients



FDG-PET/CT in Malignant Melanoma


Guidelines & Recommendations (NCCN 2007, multidisciplinary panel – JNM 2008)

The use of FDG PET/CT is recommended:

- Initial evaluation of clinical stage II and IV
- Suspected recurrence and metastases.
- In addition to conventional imaging for restaging of recurrent melanoma.



F, 62y, Breast ca, s/a surgery 2 yrs, Rising CEA




- 1. Negative FDG-PET/CT study, physiologic uptake in rectum
- 2. 2nd primary malignant tumor in rectum
- 3. Metastasis in sacral bone

FDG-PET/CT in Breast Cancer, Rising Serum Markers Occult Recurrence? The Significance of Incidentaloma in the GI Tract

Israel et al, JNM 2006


Biopsy: adenocarcinoma



- 1. Negative FDG-PET/CT study, physiologic uptake in rectum
- 2. 2nd primary malignant tumor in rectum
- 3. Metastasis in sacral bone



FDG-avid Focus in Left Chest



M, 50y, FUO

Normal CT of chest and abdomen

- 1. FDG+ uptake in chest wall, most probably recent fracture in rib
- 2. FDG+ in left breast cancer
- 3. FDG+ in left breast in a male patient of no clinical significance
- 4. FDG+ in left breast should be further evaluated



FDG-avid Focus in Left Breast




- 1. FDG+ uptake in chest wall, most probably recent fracture in rib
- 2. FDG+ in left breast cancer
- 3. FDG+ in left breast in a male patient of no clinical significance
- 4. FDG+ in left breast should be further ___ evaluated

FDG-avid focus in small nodule in left breast behind the nipple

Left breast abscess (diagnosed by US guided FNA)

FDG-avid Focus in Left Breast Assessment of Fever of Unknown Origin



FUO: 3 major etiologies:

Infections: main etiology - mostly of bacterial origin (e.g. tuberculosis, abscess, endocarditis, osteomyelitis); less frequent - viral

Malignany: mainly lymphoma, leukemia, renal cell carcinoma or liver mets

Inflammatory processes: arthritis, arteritis, inflammatory bowel disease, systemic lupus erythematosus.